As a long-term strategic partner of Taiji Group, Medicilon relies on its GMP-compliant oral solid formulation production facilities and professional formulation R&D platform to deliver pilot scale-up and clinical trial sample manufacturing services for DSC158A Tablets, supporting the smooth clinical progression of this novel innovative drug.
Urgent Unmet Clinical Needs for Influenza Prevention and Treatment
Influenza remains a persistent global public health threat. Viral mutations can trigger large-scale global pandemics, resulting in substantial unmet clinical needs worldwide. Seasonal influenza outbreaks occur annually across the globe, with major epidemics recorded in 2009 and 2023. In China, the seasonal influenza infection rate ranges from 5% to 10%, causing approximately 88,100 influenza-related respiratory deaths per year, accounting for 8.2% of total respiratory disease mortalities nationwide.Precision Viral Blockade: Innovative New Solution for Influenza Treatment
Independently developed by Taiji Group, DSC158A Tablets are a novel next-generation RNA polymerase inhibitor indicated for adult influenza A and B treatment. Preclinical studies have demonstrated that DSC158A Tablets can effectively relieve influenza symptoms in animal models at low doses, while exhibiting favorable tolerability and a broad safety window. Classified as a Class 1 New Chemical Entity, the drug features an innovative structure with no approved counterparts globally.The successful progression of DSC158A Tablets into clinical development marks a significant breakthrough for Taiji Group’s R&D pipeline in the field of innovative chemical drugs, demonstrating the Group’s R&D prowess under its innovation-driven strategy.
Empowered by Professional Platforms to Accelerate Innovative Drug Industrialization
Medicilon operates GMP-compliant production workshops for oral solid, inhalation and semi-solid preparations, enabling fully standardized manufacturing to support clinical development of innovative drugs. In addition, the company has built two core technical platforms to address key bottlenecks and drive innovation in formulation research and development:
Poorly Soluble Innovative Drug Technical Platform: Equipped with core technologies including solid dispersion, micronization, solubilization and inclusion complexation, as well as integrated in vitro dissolution and in vivo PK comprehensive evaluation systems, the platform effectively resolves common industry challenges such as poor solubility and low membrane permeability of drug candidates.
High-End Formulation Technical Platform: Focusing on cutting-edge drug delivery technologies including inhalation, ophthalmic, transdermal, sustained/controlled release and novel particulate delivery systems, the platform continuously upgrades its technical system to meet the diverse R&D demands of innovative and complex dosage forms.
